225 Franklin Street
26th Floor
Boston, MA 02110
United States
857 246 8998
https://www.pieris.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 46
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Mr. Stephen S. Yoder J.D. | CEO, President & Director | 727,19k | N/A | 1976 |
Mr. Thomas Bures | Senior VP, CFO & Treasurer | 468,74k | N/A | 1975 |
Maria Kelman | Executive Director of Investor Relations | N/A | N/A | N/A |
Dr. Shane Olwill Ph.D. | Senior VP & Chief Development Officer | N/A | N/A | 1976 |
Mr. Prompong Chaikul | Chief Supply Chain Officer | N/A | N/A | 1987 |
Dr. Florian Witte Ph.D. | VP and Head of Alliance Management & Early Project Leadership | N/A | N/A | N/A |
Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.
Pieris Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.